We are proud to announce that Lepu Medical's MemoCarna ASD occluder have officially received ANVISA approval! Since its launch in 2020 in the Chinese market, MemoCarna has become the go-to choice for ASD patients, significantly replacing the MemoPart ASD occluder. Now, with ANVISA approval, MemoCarna is ready to bring its proven effectiveness and innovation to patients in Brazil. And there's more exciting news ahead—CE certification is on the way. Together, let's look forward to a brighter future for global healthcare!
Contact us>>marketing@lepu-medical.com
Visit lepumedical website for more >>en.lepumedical.com